Preventive therapy for cancer.

@article{Cuzick2017PreventiveTF,
  title={Preventive therapy for cancer.},
  author={Jack M Cuzick},
  journal={The Lancet. Oncology},
  year={2017},
  volume={18 8},
  pages={
          e472-e482
        }
}
  • J. Cuzick
  • Published 1 August 2017
  • Medicine
  • The Lancet. Oncology

Figures and Tables from this paper

Progress in preventive therapy for cancer: a reminiscence and personal viewpoint

  • J. Cuzick
  • Medicine
    British Journal of Cancer
  • 2018
My involvement in these initiatives is recalled and a personal viewpoint on what has been achieved and what remains to be done is offered.

General Aspects of Primary Cancer Prevention

Though numerous preclinical and population-based clinical studies have already made important progress in restraining the overall cancer incidence and mortality, the full potential of preventive strategy is still far from being realized, and remains at an early stage.

Cancer Prevention Europe

The need for strengthening cancer prevention is highlighted and the objectives of Cancer Prevention Europe are introduced, with a foreseen future role in reducing the European cancer burden.

Cancer Prevention Strategies for Women.

Primary prevention strategies-those aimed at reducing the risk of developing cancer-as well as secondary prevention strategies -measures aimed at the early detection of disease are examined.

The Use of Anti-Inflammatory Agents for Cancer Chemoprevention

The present chapter recapitulates the main preclinical and clinical advances on the search for anti-inflammatory cancer chemopreventive compounds.

Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies

Future studies are needed to assess the effect of statins in risk reduction and to identify other drugs with chemopreventive potential against CBC, with only statins demonstrating promise as preventive agents and a potential treatment option for ER-negative breast cancer patients.

Breast Cancer Prevention

Given that the worldwide burden of breast cancer is nearly 1.4 million new cases, a quarter of all cancer diagnoses in women with just under half a million lives lost annually to the disease, the prevention and early detection of Breast cancer remains a major global public health priority.

Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

  • I. Jatoi
  • Medicine
    European journal of breast health
  • 2018
Management of women who carry mutations that have been associated with an increased breast cancer risk is discussed, and mammography is regarded as the optimal means of screening for breast cancer in the general population.

Chemoprevention of esophageal adenocarcinoma

Proton-pump inhibitors are the best studied and have modest EAC-chemoprevention efficacy in BE patients, with a recent randomized trial showing that high-dose PPI may be more effective than low- dose PPI.

Melatonin: A Molecule for Reducing Breast Cancer Risk

Melatonin, as a result of its antiestrogenic and antioxidant properties, as well as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could safely be associated with the antiESTrogenic drugs presently in use.
...

References

SHOWING 1-10 OF 103 REFERENCES

Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force

This article focuses on cancer mortality and incidence, with all-cause mortality and harms of aspirin use in a CVD primary prevention population and in adults without a history of CRC, familial adenomatous polyposis, or Lynch syndrome addressed.

Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?

Concerns about toxicity have limited the use of aspirin as a cancer prevention agent, but recent epidemiological evidence demonstrating regular aspirin use after a diagnosis of cancer improves outcomes suggests that it may have a role in the adjuvant setting where the risk:benefit ratio will be different.

The role of aspirin in cancer prevention

The general mechanism of action that defines aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) as a class, the specific advantages of aspirin over other NSAIDs for prophylactic use, the current evidence concerning the main health outcomes affected by aspirin use, and the hypothesis that inhibition of platelet activation may mediate both the cardioprotective and cancer-preventive effects of low-dose aspirin are considered.

Low-dose aspirin use and the risk of ovarian cancer in Denmark.

Low-dose aspirin use may be associated with a reduced risk of epithelial ovarian cancer, and the strongest inverse associations were seen for mucinous and endometrioid tumours.

Aspirin Use and Survival After Diagnosis of Colorectal Cancer

Findings show that use of aspirin after diagnosis of colorectal cancer is associated with improved survival from the disease, especially among patients with primary tumors that overexpress COX-2.

Resveratrol in the management of human cancer: how strong is the clinical evidence?

The observation that it modulates components of the insulin‐like growth factor system in the plasma of volunteers is encouraging, and the knowledge base that helps determine whether resveratrol may be useful in cancer management has increased substantially in recent years.

Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population

Screening and eradication of H. pylori infection before aspirin use could reduce the incidence of upper GI complications by 25–30 % and substantially lower aspirin-related GI harms.

Do antioxidants prevent colorectal cancer? A meta-analysis.

  • R. PaisD. Dumitrascu
  • Medicine
    Romanian journal of internal medicine = Revue roumaine de medecine interne
  • 2013
This meta-analysis found no evidence in favor of a protective effect of the studied antioxidant supplements in the prevention of colorectal cancer or cancer related mortality.

Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials.

Large numbers of candidate substances such as phytochemicals and their synthetic derivatives have been identified by a combination of in vitro and in vivo studies in a wide range of biological assays, however, a comprehensive description of these chemopreventive agents has not been extensively reviewed.
...